Results 251 to 260 of about 7,630,796 (295)
Some of the next articles are maybe not open access.
Improving the targeting of therapeutics with single-domain antibodies
Expert Opinion on Drug Delivery, 2016The targeted delivery of therapeutic agents greatly increases their effectiveness while simultaneously reducing negative side effects. In the past, targeting of therapeutics has been accomplished with nucleic acids, peptides/proteins, and conventional antibodies. A promising alternative to the conventional antibodies often used in therapeutic targeting
Kendrick B, Turner +3 more
openaire +2 more sources
Engineered antibody fragments and the rise of single domains
Nature Biotechnology, 2005With 18 monoclonal antibody (mAb) products currently on the market and more than 100 in clinical trials, it is clear that engineered antibodies have come of age as biopharmaceuticals. In fact, by 2008, engineered antibodies are predicted to account for >30% of all revenues in the biotechnology market. Smaller recombinant antibody fragments (for example,
Philipp, Holliger, Peter J, Hudson
openaire +2 more sources
Prospective Applications of Single-Domain Antibodies in Biomedicine
Molecular Biology, 2020Methods that utilize highly specific antibodies, anti-idiotypic antibodies, various recombinant molecules with antibody properties and immunocorrection and immunoprophylaxis with the help of vaccines are in demand and are intensely developed in the field of biomedicine.
openaire +2 more sources
Expression of single-domain antibody in different systems
Applied Microbiology and Biotechnology, 2017Camelid single-domain antibodies (sdAbs, VHHs, or Nanobodies®) are types of antibody fragments that are composed of the heavy-chain variable domain only. These VHHs possess unique structural and functional features, as they are small in size and exhibit thermal stability and high solubility. Compared to conventional antibodies, VHHs can be manufactured
Yongkang, Liu, He, Huang
openaire +2 more sources
Bispecific Single Domain Antibodies
2011Monoclonal antibodies are now widely recognized as therapeutic molecules and more than 25 molecules have been approved in the United States and other countries. Despite these successes, the clinical activity of these molecules is still far from optimal and new solutions have to be found, especially in the field of cancer therapy.
Patrick Chames, Daniel Baty
openaire +1 more source
2006
Classical antibodies are complex assemblies, difficult to produce in bacteria, and too bulky for many medical or research applications. Therefore, substantial efforts aimed at finding simpler miniaturised antibodies. Heavy-chain antibodies in camelids are a natural source of such mini-antibodies. Moreover, their antigen-binding domain (named Nanobody),
openaire +1 more source
Classical antibodies are complex assemblies, difficult to produce in bacteria, and too bulky for many medical or research applications. Therefore, substantial efforts aimed at finding simpler miniaturised antibodies. Heavy-chain antibodies in camelids are a natural source of such mini-antibodies. Moreover, their antigen-binding domain (named Nanobody),
openaire +1 more source
Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody
Cell, 2022Cheng Li, Jiang Shibo, Lu Lu
exaly
Immunogenicity and humanization of single-domain antibodies
FEBS Journal, 2022Jamshid Tanha, Kevin A Henry
exaly